Replimune Group, Inc.

Fundamentals3.0
Price Action4.0
News Sentiment2.0
AI Rating
4.0

Key Drivers

  • Strong Net Cash
  • Rapid Cash Burn
  • Ongoing Dilution

AI
AI Summary

4.0

REPL's investment case hinges on verifying TujuCare's true FDA/label status and proving early launch adoption fast enough to offset roughly $76M quarterly cash burn and avoid dilutive financing; absent confirmed revenue traction, the stock appears to price in more success than its balance sheet supports.

CommercialUpside
DilutionRisk
FDAStatus‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

3.0

Key Financial Insights:

  • •Strong Net Cash
  • •Rapid Cash Burn
  • •Ongoing Dilution

REPL has strong net cash and liquidity, but rapid cash burn, no revenue, heavy R&D losses, rising leverage, and shareholder dilution create significant funding and execution risk.

CashBurn
LiquidityRisk

Price Behavior

4.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • •Lower highs
  • •Support test
  • •Elevated RSI

REPL is in a short-term downtrend; defend $12.87–$12.92 and reclaim $13.30 to improve the setup, while a break below support risks further volatility.

REPL
TechnicalAnalysis
Support Level: $12.87–$12.92
Resistance Level: $13.20–$13.30; $14.45–$14.77

Sharp rally followed by an 11.5% decline over the last month

Sentiment & News

2.0

Key News Insights:

  • •Securities Litigation
  • •FDA Disclosure
  • •Share Decline

Replimune faces securities class-action scrutiny over alleged undisclosed FDA concerns surrounding RP1 trial design and efficacy evidence, heightening investor risk after a sharp share-price decline.

LegalRisk
FDAConcerns

The litigation and regulatory allegations could sustain negative pressure on REPL shares pending clearer FDA and trial-data updates